| Literature DB >> 29166903 |
B A McGivney1, M E Griffin2, K F Gough1, C L McGivney1, J A Browne1, E W Hill1, L M Katz3.
Abstract
BACKGROUND: Circulating miRNAs (ci-miRNAs) are endogenous, non-coding RNAs emerging as potential diagnostic biomarkers. Equine miRNAs have been previously identified including subsets of tissue-specific miRNAs. In order to investigate ci-miRNAs as diagnostic tools, normal patterns of expression for different scenarios including responses to exercise need to be identified. Human studies have demonstrated that many ci-miRNAs are up-regulated following exercise with changes in expression patterns in skeletal muscle. However, technical challenges such as haemolysis impact on accurate plasma ci-miRNA quantification, with haemolysis often occurring naturally in horses following moderate-to-intense exercise. The objectives of this study were to identify plasma ci-miRNA profiles and skeletal muscle miRNAs before and after exercise in Thoroughbreds (Tb), and to evaluate for the presence and effect of haemolysis on plasma ci-miRNA determination. Resting and post-exercise plasma ci-miRNA profiles and haemolysis were evaluated in twenty 3 year-old Tbs in sprint training. Resting and post-exercise skeletal muscle miRNA abundance was evaluated in a second cohort of eleven 2 year-old Tbs just entering sprint training. Haemolysis was further quantified in resting blood samples from twelve Tbs in sprint training. A human plasma panel containing 179 miRNAs was used for profiling, with haemolysis assessed spectrophotometrically. Data was analysed using a paired Student's t-test and Pearson's rank correlation.Entities:
Keywords: Exercise; Haemolysis; Horse; Plasma; Skeletal muscle; miRNA
Mesh:
Substances:
Year: 2017 PMID: 29166903 PMCID: PMC5700565 DOI: 10.1186/s12917-017-1277-z
Source DB: PubMed Journal: BMC Vet Res ISSN: 1746-6148 Impact factor: 2.741
Fig. 1Box and whiskers plot depicting the degree of haemolysis based on absorbance at 414 nm for n = 13 equine plasma samples before and after exercise (cohort A) and from n = 12 equine plasma sampes from horses at rest (cohort C). A value of ≤0.2 absorption units was used as the threshold for acceptable haemolysis and accurate quantification of ci-miRNA detection. The red line indicates the threshold above which accurate quantification of ci-miRNA is not possible
Fig. 2Heatmap showing the levels of 52 miRNAs relative to the degree of haemolysis from n = 13 equine plasma samples before and after exercise. MiRNA abundance is presented as C t values and degree of haemolysis is the absorbance at 414 nm for each plasma sample
Fig. 3Real time qRT-PCR results for miRNAs differentially expressed in skeletal muscle before and following exercise from n = 11 Thoroughbred horses. The standard 2-ΔΔCT method was used to determine mean fold changes in gene expression. All Ct values were normalised using the global normalisation function in the GeneEx software package. A Student’s t-test was used to identify significant differences in mRNA abundance between time-points
The most over-represented KEGG pathways for each miRNA based on a predicted target gene list
| miRNA | Fold change | adjusted |
| Top KEGG pathway |
|
|---|---|---|---|---|---|
| hsa-let-7d-3p | −0.68 | 0.002 | 3 | NA | NA |
| hsa-miR-21-5p | 0.92 | 0.002 | 243 | Cytokine-cytokine receptor interaction | 2.48E-06 |
| hsa-let-7d-5p | −0.44 | 0.022 | 370 | ECM-receptor interaction | 9.22E-06 |
| hsa-miR-30b-5p | 0.52 | 0.023 | 1113 | Ubiquitin mediated proteolysis | 4.76E-10 |
| hsa-miR-30e-5p | 0.64 | 0.042 | 1153 | Ubiquitin mediated proteolysis | 2.92E-08 |
Pathways previously implicated in the equine exercise response that were significantly enriched among predicted targets of the differntially expressed miRNAs
| KEGG pathway |
|
|
|
|---|---|---|---|
| B cell receptor signalling pathway | 1.4637E-06 | 16 | 4 |
| Ubiquitin mediated proteolysis | 1.4637E-06 | 25 | 4 |
| Neurotrophin signalling pathway | 3.75787E-06 | 22 | 4 |
| T cell receptor signalling pathway | 3.75787E-06 | 20 | 4 |
| TGF-beta signalling pathway | 9.00943E-06 | 15 | 4 |
| PI3K-Akt signalling pathway | 4.61509E-05 | 43 | 4 |
| Long-term potentiation | 0.000171436 | 13 | 4 |
| Regulation of actin cytoskeleton | 0.000171436 | 28 | 4 |
| MAPK signalling pathway | 0.000293552 | 34 | 4 |
| Jak-STAT signalling pathway | 0.000485158 | 22 | 4 |
| Axon guidance | 0.000671812 | 22 | 3 |
| Arrhythmogenic right ventricular cardiomyopathy | 0.000834821 | 13 | 3 |
| Hepatitis B | 0.000838527 | 21 | 4 |
| Transcriptional misregulation in cancer | 0.002038503 | 26 | 4 |
| Hypertrophic cardiomyopathy | 0.002113538 | 13 | 3 |
| Insulin signalling pathway | 0.002113538 | 19 | 4 |
| Mucin type O-Glycan biosynthesis | 0.002113538 | 6 | 3 |
| Prostate cancer | 0.0021797 | 13 | 4 |
| mTOR signalling pathway | 0.002349162 | 11 | 4 |
| Acute myeloid leukaemia | 0.003086604 | 9 | 4 |
| Adherens junction | 0.004193219 | 14 | 4 |